STOCK TITAN
  1. Home
  2. Sec-filings
  3. TLSI
  4. [Form 4] TriSalus Life Sciences, Inc. Insider Trading Activity

TriSalus Life Sciences Discloses Director Option Grant in Form 4

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

TriSalus Life Sciences, Inc. (TLSI) filed a Form 4 on 27-Jun-2025 for director Arjun J. Desai. On 12-Jun-2025 Desai received a grant of 15,000 non-qualified stock options at an exercise price of $5.50 per share. The options will fully vest on the earlier of (i) 12-Jun-2026 or (ii) the company’s next annual shareholder meeting, subject to continued service. They expire on 11-Jun-2035. After this grant, Desai beneficially owns 65,000 derivative securities; no common shares were acquired or sold, and ownership remains direct. The filing represents routine director compensation and does not disclose any open-market transactions.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine director option grant; neutral governance signal.

The Form 4 discloses standard board compensation—a 15,000-option award at $5.50, vesting within 12 months. No sales, pledges, or unusual structures are noted, and ownership stays direct. From a governance standpoint, granting options aligns director incentives with shareholder value but is a customary practice, so the disclosure is informational rather than market-moving.

TL;DR: No buy/sell; minimal portfolio impact.

The insider did not purchase or dispose of common stock; instead he accepted routine equity compensation. Exercise price of $5.50 is only relevant if shares appreciate. With 65,000 options outstanding, dilution risk is immaterial relative to TLSI’s float. I view the filing as operationally neutral and unlikely to influence valuation or trading strategy.

Insider Desai Arjun JJ
Role Director
Type Security Shares Price Value
Grant/Award Director Stock Option (right to buy) 15,000 $0.00 $0.00
Holdings After Transaction: Director Stock Option (right to buy) — 65,000 shares (Direct)
Footnotes (1)
  1. F1. The shares subject to the option shall fully vest on the one-year anniversary of the grant date of June 12, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Desai Arjun JJ
(Last) (First) (Middle)
6272 W. 91ST AVENUE
(Street)
WESTMINSTER CO 80031
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Director Stock Option (right to buy) $5.5 06/12/2025 A 15,000 (1) 06/11/2035 Common Stock 15,000 $0 65,000 D
Explanation of Responses:
1. The shares subject to the option shall fully vest on the one-year anniversary of the grant date of June 12, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer.
Remarks:
/s/ Mary Szela, Attorney-in-Fact 06/27/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR